Albireo Pharma Inc EV/EBIT
Qual é o EV/EBIT de Albireo Pharma Inc?
O EV/EBIT de Albireo Pharma Inc é N/A
Qual é a definição de EV/EBIT?
Enterprise value to earnings before interest and taxes (EV/EBIT) is a financial ratio used to measure if a stock is priced appropriately to similar stocks and the market. It is similar to the P/E ratio.
ttm (trailing twelve months)
The EV/EBIT ratio addresses some of the shortcomings of the P/E ratio. Instead of taking market capitalization, the ratio uses enterprise value, as it takes into account the true value of the company. Enterprise value includes both equity and debt. It is calculated as:
Enterprise value = market cap + total debt – cash and cash equivalents
The EV/EBIT ratio is useful in comparing peers within the wider market. A high EV/EBIT ratio indicates that a company’s stock is overvalued. On the opposite, a low EV/EBIT ratio indicates that a company’s stock is undervalued. The lower the ratio, the more financially stable a company should be. However, investors and analyst should use other ratios and information to get a full picture of a company’s financial state and actual value.
EV/EBIT de empresas na Setor Health Care em NASDAQ em comparação com Albireo Pharma Inc
O que Albireo Pharma Inc faz?
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Empresas com ev/ebit semelhantes a Albireo Pharma Inc
- S.A.L. Steel tem EV/EBIT de N/A
- Baring Emerging Europe Plc tem EV/EBIT de N/A
- Invesco Income Growth Trust Plc tem EV/EBIT de N/A
- Rozdil Capital tem EV/EBIT de N/A
- Elsight tem EV/EBIT de N/A
- Saint Jean Carbon tem EV/EBIT de N/A
- Albireo Pharma Inc tem EV/EBIT de N/A
- Vitality Biopharma tem EV/EBIT de N/A
- Spir Communication tem EV/EBIT de N/A
- ArcPacific Resources tem EV/EBIT de N/A
- 92 Ltd tem EV/EBIT de N/A
- Chembio Diagnostics tem EV/EBIT de N/A
- Jiulian Resources tem EV/EBIT de N/A